| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 9715 | DOTA-[Pro1,Tyr4]bombesin (1-14) |
9715.0001: 1 mg per vial 9715.0010: 10 mg per vial Please inquire for customized filling and bulk quantities.
|
|
Precursor for radiolabelled DOTA-[Pro1,Tyr4]bombesin (1-14)
|
||
| Molar Mass: 2042.28 | ||
| C90H136N28O25S< | ||
| [593287-40-2] (net peptide) | ||
| Colourless to off-white freeze-dried solid packaged in screw cap vials. | ||
| Purity: ≥ 95 % | ||
|
Certificates:
CoA; MS (identity); HPLC (purity) |
||
|
Chemical Name: Sequence: DOTA-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 DOTA = [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl Supplied as acetate salt |
||
|
Synonymes: Bombesin, 1-[1-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-; MP2346; DOTA-[P1, Y4]BBN(1-14); CA index name: Bombesin, 1-[1-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine- |
||
|
Literature: Biddlecombe G.B. et al. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice Using 64Cu- and 86Y-DOTA-[Pro1,Tyr4]-Bombesin(1-14). Bioconjug Chem. 2007, 18, 724-30. |
||
| Breeman W.A. et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999, 81, 658-65. | ||
| Breeman W.A. et al. Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43, 1650-56. | ||
| date of product catalogue issue: 10 May 2017 | ||